$VRCA News

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To Distribute YCANTH For The Treatment Of Molluscum Contagiosum With Up To $8.2M In Milestones

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call

Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call

Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...

Verrica Pharmaceuticals Q1 Earnings Call Highlights

Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript

Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

Verrica Pharmaceuticals Q1 Adj. EPS $(0.41) Misses $(0.38) Estimate, Sales $5.023M Beat $4.520M Estimate

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Verrica Pharma To Present Phase 2 Clinical Data Highlighting Potential Abscopal Effects Of Oncolytic Peptide, VP-315, In Treatment Of Basal Cell Carcinoma At 2026 SID Annual Meeting

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Verrica Pharmaceuticals Reveals Acceptance Of A Late-breaking Abstract Reporting Phase 2 Exploratory Data Of VP-315; Data To Be Presented At The Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference